Patients who have received prior treatment with GEN-1.Patients must be at least 18 years old.Patients must have signed an IRB-approved informed consent and authorization permitting release of personal health information.Patients must have satisfactory results for the baseline laboratory analyses and diagnostic procedures as specified in the protocol.If applicable, patients must discontinue breastfeeding prior to study entry.

Patients of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception.

Patients must have a performance status score of 0, 1 or 2 by Eastern Cooperative Group (ECOG) criteria.

Continuation of hormone replacement therapy is permitted.

Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment.

Patients should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within four weeks of study entry.

Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1.

SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN.

Hepatic function: Bilirubin ≤ 1.5 x ULN.

Renal function: Creatinine ≤1.5 x institutional upper limit normal (ULN).

Platelets greater than or equal to 100,000/mcl. This ANC cannot have been induced or supported by granulocyte colony stimulating factors.

Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl.

Patients with the following histologic epithelial cell types are eligible: High grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.).

Patients must have an International Federation of Gynecology and Obstetrics (FIGO) of III or IV.

Histologic documentation of the original primary tumor is required via the pathology report.

Patients must have suspected histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma per pre-treatment biopsies by laparoscopy, or interventional radiology or CT guided core biopsy.

Why Should I Register and Submit Results?.

Ovation model numbers